TP53 and triple-negative breast carcinoma: By targeting CDC7, p53-mutant HER2-overexpressing and triple-negative breast cancer cells undergo an abortive S phase and apoptotic cell death, suggesting the potential therapeutic effect of CDC7 in p53-mutant breast cancers [29].